Browse

You are looking at 221 - 230 of 307 items for :

  • Refine by Content Type: All x
Clear All Modify Search

Adding to previous studies suggesting that illicit drug use is associated with the development of chronic kidney disease (CKD), new research indicates that it may also put patients with established CKD at elevated risk of disease progression and early death.

In the Clinical Journal of the American Society of Nephrology study, researchers assessed whether behavioral risk factors—including tobacco, alcohol, and illicit drug use, all of which may exhibit direct or indirect nephrotoxic effects—have an impact on the outcomes of patients with CKD.

They found that persistent use of hard illicit drugs was linked with a 25% higher risk

Bridget M. Kuehn

An uptick of thrombotic microangiopathy (TMA) cases with a presentation similar to that of a rare blood disorder, thrombotic thrombocytopenic purpura, at Wake Forest Baptist Health in Winston-Salem, North Carolina, tipped off hematologist Peter Miller, MD, that something unusual was going on. An assistant professor at Wake Forest University, Miller had read a report from the U.S. Centers for Disease Control and Prevention (CDC) about similar cases linked to the illicit intravenous injection of a newly reformulated version of extended-release oxymorphone, Opana ER, so he and his colleagues began asking patients with suspected cases whether they had injected this oral

Mary Jane Gore

Older kidney recipients can benefit from organs from older donors. But previous cerebrovascular disease may reduce the survival benefits of these kidney transplants, according to a recent study.

Living donors are now getting their due as a medical population of interest that will be officially monitored for health outcomes and other data over time.

A pilot study at 10 transplant centers began enrolling donors for the Living Donor Collective, a living donor registry, in January 2018 and will enroll through September 2019 (Table 1). After that, the registry will begin enrolling at other transplant programs nationwide. A wide

Bridget M. Kuehn

Kristi Ouimet is hopeful her 15-year-old daughter will be admitted into a clinical trial of an experimental treatment for hyperoxaluria, a rare kidney condition that causes formation of painful and even life-threatening kidney stones. If she is enrolled in the trial, it will require a monthly commute from California to Minnesota for 2 years. But she’s not deterred. She’s already managed 2 years of a 6-day-per-week commute for 4 hours of daily dialysis plus 7 days a week of peritoneal dialysis for her younger son, who is also affected by hyperoxaluria and required a kidney and liver transplant.

“[If] driving

HenleA case for you, sir!
The detective sits facing the window, awaiting the arrival of his new students.
Nephron(curious): Finally, something that might put an end to this utter boredom.
HenleIt’s a case of hyperkalemia.
Nephron(smiling): Ah, yes. Electrolyte disorders. The best part of nephrology! Nevertheless, no patient will thank you for fixing their acidosis.
AldoThis is an 81-year-old man with a serum potassium level of 7.5 mmol/L.
Nephron(interrupting): I don’t need any of that information…. Oh, new fella! Dr. Aldo, welcome to nephrology. And you have a
Tracy Hampton

A new study points to factors involved in the reduced likelihood of rejection in liver-kidney transplant recipients compared with solitary kidney transplant recipients.

“For many years, transplant physicians and researchers have known that the liver transplant recipients require less immunosuppression than the recipients of other organs, to prevent rejection,” said Timucin Taner, MD, PhD, a transplant surgeon at the Mayo Clinic and lead author of the Kidney International study. “This has been attributed to the liver being less immunogenic compared to the other commonly transplanted organs; however, the liver itself is an immunologically active organ, so we hypothesized

Zach Cahill

Urgency and innovation are frequent themes in the kidney community. The Kidney Health Initiative (KHI) holds an annual meeting to translate these themes into reality. A public-private partnership with the U.S. Food and Drug Administration (FDA) and over 90 companies and organizations from various stakeholder groups in the kidney community, KHI was established to spur innovation and enhance patient safety.

Patients took center stage at the 2018 KHI Stakeholders Meeting, held in Silver Spring, MD, May 14–15. Each session at the meeting included a patient or care partner who provided the patient perspective on the session topic. Their personal stories

José J. Reyes-Tomassini

The concept of glomerular filtration rate (GFR) and its regulation is central in renal physiology. Estimates of GFR are often used in the clinical setting to assess kidney health. GFR is an effective measure of kidney function (1). Many pathophysiologic conditions affect GFR by altering the glomerular capillary pressure, including diabetes mellitus and essential hypertension. Afferent and efferent arteriole resistance plays a crucial role in the regulation of GFR. Whereas dilation of the afferent arteriole causes an increase in GFR, dilation of the efferent arteriole decreases GFR (2, 3). The concept is familiar to

Grace Squillaci

Smartphones, iPads, insulin pumps, and pharmacogenomics: these are all technology developments made in the past 50 years.

While the world around us has exploded with technological advancements, the way we provide dialysis has changed very little in 50 years. Most people with kidney failure still endure treatment sessions of 4 to 6 hours three times a week in a dialysis center. The process is intrusive and affects their quality of life as they are tethered to a schedule and a machine. Not only can travel be restrictive, but maintaining a job and family life can be a challenge as well.

Reverend Kimberly Headley
Am I my brother’s or my sister’s keeper?

I live in a community with minimal services offered to those residents who struggle with unemployment and inadequate healthcare. I live in a community where the life expectancy is 10 years less than in other parts of Brooklyn and Manhattan. I live in a community where the infant mortality rate is twice that of Brooklyn as a whole and eight times that of Manhattan’s Upper East Side. Here the premature mortality rate is twice that of Brooklyn and New York City as a whole and five times that of Manhattan’s financial district.